J&J prostate cancer combination lowers PSA in small early study
SeventyFour/iStock via Getty Images
Johnson & Johnson (JNJ) on Sunday said an experimental immunotherapy combination reduced a blood marker of prostate cancer activity by at least half in 11 of 15 patients receiving the recommended regimen in an early-stage trial. The treatment combines pasritamig
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.